Home » Medical Devices » Companion Diagnostics Market

Companion Diagnostics Market By Technology Type (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Mass Spectrometry, Others); By Indication (Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Others); By End User (Hospitals, Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Companion Diagnostics Market Size 2023	USD 5815.2 Million
Companion Diagnostics Market, CAGR	13.3%
Companion Diagnostics Market Size 2032	USD 17890.97 Million

Market Insights

The global demand for companion diagnostics was valued at USD 5815.2 Million in 2023 and is expected to reach USD 17890.97 Million in 2032, growing at a CAGR of 13.3% between 2024 and 2032.
Next-generation sequencing (NGS) is the market leader by technology type, accounting for more than 25% of total value in 2023, while the mass spectrometry segment is likely to grow substantially in the forecast time frame.
Diagnostic laboratories are expected to expand at the highest rate over the projection period, while the hospital end-user category leads the global market in 2023 with a 30% share.
Cardiovascular diseases dominate the market with 28% of the total revenue share by indication segment. In contrast, autoimmune diseases will expand fastest in the projected period.
North America continues to propel the robust growth of the companion diagnostics industry, accounting for more than one-third of the global market in 2023, while Europe and the Asia Pacific combined account for just under 56%. In 2023, Europe had a market share of more than 22%.
Companion diagnostics are medical devices or tests used in conjunction with specific drugs or treatments to help identify patients who will benefit the most from those treatments.
The primary goal of companion diagnostics is to personalize medical treatments and enhance patient outcomes by ensuring that the correct medication is administered to the right patient at the appropriate time.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Executive Summary

Market Definition

Companion diagnostics are clinical devices, typically in vitro, that offer the information required for the secure and efficient administration of a corresponding drug or biological product. Companion diagnostics are classified into two types: safety testing and predictive tests. Safety tests are performed to identify people who are prone to have adverse responses or for whom the medication may be ineffective due to genetics or other biological characteristics. This ensures that therapies are only offered to those who will benefit and prevents treatment from harming others. Predictive tests assist in the identification of patients who are more likely to respond positively to a specific treatment. This enables a more personalized healthcare approach by limiting targeted therapies to suitable patients.

Market Overview

The global companion diagnostics market has witnessed consistent growth over recent years and is set to grow at a CAGR of 13.3% between 2024 and 2032. The market was valued at USD 5815.2 million in 2023 and is expected to reach USD 17890.97 million in 2032.

The rise in product launches, the discovery of new biomarkers for a wide range of diseases, the development of targeted therapies, the demand for customized medicine with growing recognition in developing markets, and the increased number of unmet cancer care needs are all expected to contribute to the substantial growth of the global companion diagnostics market size. For instance, Amoy Diagnostics Co. Ltd and PREMIA Holdings (HK) Ltd introduced the AmoyDx Pan Lung Cancer PCR Panel (the PLC Panel) in Japan in January 2022 as a reimbursed companion diagnostic for several anti-cancer agents.

Moreover, the growing focus on personalized treatments and the co-development of pharmacological and diagnostic technologies are propelling the companion diagnostics market forward. In addition, the growing number of adverse drug reactions caused by medicine ineffectiveness necessitates the development of companion diagnostics. Globally, the increased cancer burden promotes demands and awareness for personalized medications among the general population. For example, the Australian Institute of Health & Welfare estimates that in December 2021, around 151,000 Australians had been diagnosed with cancer (413 per day), with 49,000 deaths (135 per day).

Companies are increasing their collaborations for better biological indicators and diagnostics to address cost regulations, which has opened up many market opportunities for applications in indications such as cancer, cardiovascular disease, and neurological disorders. As a result, these factors have a positive impact on the market development for companion diagnostics. However, the higher costs of medication research, clinical trials, and reimbursement challenges in many countries are projected to limit market expansion.

Segmentation by Technology Type

Next-generation sequencing (NGS) continues to dominate as the preferred technology among healthcare providers, capturing a significant revenue share of over 25% in terms of market value in 2023. Its high throughput capabilities and ability to analyze large amounts of genetic data make it indispensable in companion diagnostics.
Mass spectrometry is anticipated to expand rapidly due to technological developments and increased utilization in clinical laboratories. Its versatility in analyzing biomolecules and detecting molecular fingerprints makes it a key growth category in the companion diagnostics industry.

Segmentation by Indication

Cardiovascular diseases emerge as the dominant indication category, commanding a significant revenue share of over 28% in 2023. The increasing prevalence of cardiovascular disorders globally, coupled with the growing emphasis on early detection and personalized treatment approaches, propels the demand for companion diagnostics in this segment.
The autoimmune diseases category is likely to witness the largest market CAGR, attributed to the rising incidences of autoimmune disorders and the growing adoption of companion diagnostics for accurate disease diagnosis, prognosis, and treatment monitoring. Advances in biomarker discovery and targeted therapies further lead to growth opportunities in this segment.

Segmentation by End User

Specialty clinics and diagnostic laboratories collectively serve a substantial portion of the global market needs for companion diagnostics, owing to their expertise in disease-specific testing and personalized treatment strategies. These facilities play a central role in delivering timely and accurate diagnostic services to patients across various medical specialties.
Hospitals emerged as the leading end users in the companion diagnostics market, contributing to over 30% of the market share in 2023. The extensive infrastructure, diverse patient populations, and integrated healthcare delivery models in hospital settings make them key adopters of companion diagnostics for comprehensive disease management and patient care.

Segmentation by Region

North America stands out as the leading global market for companion diagnostics, contributing to over one-third of the revenue growth in 2023. This region mainly benefits from robust healthcare infrastructure, favorable reimbursement policies, and a strong focus on personalized medicine initiatives.
Europe and Asia Pacific collectively account for just under 56% of the share in 2023, with Europe holding over 22% in the same year. These regions witness significant adoption of companion diagnostics attributed to developments in healthcare technology and increasing awareness of personalized medicine.
The rest of the world, including Latin America, the Middle East, and Africa, represents emerging markets with growing demand for companion diagnostics. Factors such as improving access to healthcare services, expanding diagnostic capabilities, and rising awareness about personalized medicine contribute to these regional market’s growth trajectory.

With a market share of more than 36.5% in 2023, North America represents the largest portion of the global companion diagnostics market. North America, notably the United States and Canada, dominates the companion diagnostics industry due to its technological innovations. The continuously rising product approvals by regulatory authorities are supporting the companion diagnostics market share growth throughout the forecast period. For example, in October 2022, F. Hoffmann-La Roche Ltd., a pharmaceutical company, received U.S. FDA authorization for the first companion diagnostic for identifying patients with HER2 (human epidermal growth factor receptor 2) low metastasis breast cancer.

Europe is the fastest-growing companion diagnostics market, accounting for more than 22% of total revenue in 2023. In Europe, real-time PCR techniques are becoming more popular for infectious disease diagnostics. As per the European Centre for Disease Prevention & Control, real-time polymerase chain reaction (PCR) assays are commonly used in Europe to diagnose hospital-acquired infections.

Asia-Pacific offers lucrative opportunities for major players in the companion diagnostics market due to its large population base, growing awareness of companion diagnostics, growth in healthcare facilities, and increased demand for advanced therapeutics. The use of next-generation sequencing (NGS) has increased dramatically over the last five years throughout the Asia-Pacific marketplace, particularly in China, Japan, India, and South Korea. Government organizations in these countries have started large-scale genome sequencing studies to gain a deeper understanding of the genetic differences within their populations.

Key Highlights of the Report

The global companion diagnostics market is segmented by technology type, indication, end user, and region. Next-generation sequencing (NGS) remains the favored technology type among healthcare providers due to its high-throughput capabilities and comprehensive genetic analysis potential. Cardiovascular diseases and autoimmune diseases emerge as dominant indications, owing to the significant need for companion diagnostics to guide personalized treatment approaches for these conditions. Specialty clinics, diagnostic laboratories, and hospitals all serve major market end-users, widely utilizing their expertise and infrastructure to generate strong demand for companion diagnostic tests.

The emergence of personalized medicine generated an evolutionary shift in the healthcare industry. Numerous have been identified over the years in which traditional treatment approaches have failed to provide any therapeutic benefit. It has been estimated that over 50% of recommended medications and therapies fail to deliver adequate clinical benefits. In fact, negative drug reactions or side effects are considered the fourth largest cause of fatalities in the United States. The use of these companion diagnostic technologies helps doctors decide whether a particular therapy plan is best for the patient in the long run. One of the main factors supporting the requirement for more precise and customized treatment choices is the increasing prevalence of cancers throughout the world.

Companion diagnostics assist in the selection of targeted medicines that are appropriate for patients based on their genetic composition and expected response. This is predicted to enhance treatment outcomes while reducing the adverse effects of inappropriate drugs. Moreover, regulatory approvals for multiple targeted oncology drugs, in combination with complementary companion diagnostics, are contributing to market expansion. However, higher assay development expenses and lengthy approval periods remain market barriers to overcome. Limited evidence from clinical studies validating companion diagnostic tests can sometimes impede their widespread market acceptance and insurance coverage. Nonetheless, technical improvements that allow for the simultaneous screening of several biomarkers are helping to resolve these challenges.

The North American region dominated the overall companion diagnostics market share, with the U.S. emerging as a major revenue contributor. The inclusion of companion diagnostics is regarded to be an essential treatment preference tool for numerous oncology therapies, as seen by how the FDA defines these assays in terms of risk. In the pharmaceutical sector, companion diagnostics clinical trials have gained prominence despite the COVID-19 pandemic as they increase the likelihood of clinical success. The rising cancer burden in the United States is also predicted to boost market size. As the American Cancer Society reported, 1.9 million new cancer cases were diagnosed in the U.S. by the end of 2022. The majority of companion diagnostics users in the U.S. also have chronic illnesses, which further propels the market’s expansion.

What Are The Main Drivers Of The Global Companion Diagnostics Market?

The increasing incidences of thalassemia, HIV, melanoma, breast cancer, gastric cancer, colorectal cancer, and lung cancer are driving up the market need for companion diagnostic procedures. Companion diagnostic tests are becoming more and more in demand for the early screening and identification of chronic illnesses. These tests also serve to reduce drug side effects, improve patient outcomes, give high diagnostic accuracy and specificity, reduce pharmacotherapy variability, and find the most effective targeted therapeutic alternatives. They are also connected with increased drug development success. Rising cancer occurrences and lower drug development costs are further helping to boost the global companion diagnostics market share.

What Are The Major Challenges Faced By The Global Companion Diagnostics Market?

While immunotherapy has shown tremendous potential in cancer treatment, the exorbitant cost has hampered overall patient access. Physicians may prefer to combine medicines, which could increase the therapy length from five months to more than three years. In this scenario, the longer the time, the higher the cost. Personalized immunotherapies are also very expensive. Immunotherapies for cancer can be quite expensive compared to other forms of treatment like radiation or chemotherapy. Thus, the expensive nature of immuno-oncology treatments is projected to hinder the growth of the companion diagnostics market.

What Are The Growth Opportunities In The Global Companion Diagnostics Market?

Personalized or targeted therapeutics are one of the most promising market trends in medical research. It is one of the most important fields that generate market demand for companion diagnostics devices. Healthcare providers are working on leveraging CDx to develop novel treatments based on unique genetic biomarkers across major domains such as oncology, heart disease, inflammation, central nervous system disorders, infectious illnesses, and many others to optimize patient outcomes. Growing rates of breast cancer around the world also contribute to the market growth for companion diagnostics, generating value-grab opportunities for industry players.

Market Drivers

Several factors contribute to the growth of the global intraosseous device market. The primary factors propelling the global companion diagnostics market are as follows:

Increased Cancer Prevalence and the Need for Targeted Therapies

Cancer has been increasingly prevalent in recent years. The increasing number of cancer cases necessitates the use of effective CDx assays, as genomic testing provides doctors with a detailed image of patients’ tumors and precise insights into treatment procedures. Thus, the rising occurrence of cancer is driving up sales of CDx products. Canadian cancer statistics show that 229,200 new cancer cases were detected in November 2021. Also, the WHO (World Health Organisation) reports that in 2022, there will be 2.26 million new instances of breast tumors and 2.21 million cases of lung cancer worldwide. In lung cancer, companion diagnostic tests are regarded as mandatory in decision-making to proceed with targeted therapy. The survival benefits of companion diagnostics for lung cancer patients are greater than those of those who do not receive them throughout their initial course of treatment.

Furthermore, novel tests for diagnosing certain types of mutations are being developed in response to an increasing need. For instance, the FDA in the United States authorized Guardant360 CDx in August 2020. This is the first liquid biopsy companion diagnostic that employs next-generation sequencing technology to detect patients with certain types of epidermal growth factor receptor (EGFR) gene mutations in metastatic non-small cell lung cancer. This factor has resulted in broad demand for these assessments and is responsible for the market’s expansion throughout the forecast period.

Market Restraints

The global companion diagnostics market faces certain challenges that may limit its growth. These consist of the following:

Incompetent Reimbursement Scenarios and Stringent Regulations

The lack of a standardized procedure to determine the reimbursement fee for a companion diagnostic test persists despite growing market acceptability. The reimbursement amount is determined on an individual basis. For example, according to a June 2022 article released by Taylor Wessing LLP in Germany, reimbursement for these companion diagnostic tests differs across inpatient and outpatient settings. Diagnostics are mostly handled by diagnosis-related organizations within the inpatient care system. Outpatient treatment is reimbursed in accordance with the specific catalog of reimbursable treatments.

Moreover, companion diagnostics (CDx) do not have a consistent regulatory framework. There are multiple challenges associated with the clinical development and regulation of companion diagnostics, which plays a vital role in terms of sensitivity and specificity when making a therapeutic decision. The European Union is actively implementing regulations governing in vitro diagnostic medical devices (IVDR). This new regulation imposes a number of rigorous standards for scientific validity and clinical efficacy.

As per a 2021 article by Biomarker Insights in the National Library of Medicine, a conformity assessment procedure between a medical authority and a designated body is mandatory for the CDx compliance evaluation process. The consultation lasts more than 60 days and can be extended for another 60 days. The primary factors behind the adoption of these devices are often appropriate reimbursement schemes and laws. As a result, a lack of reimbursement and stringent regulations impede probable global companion diagnostics market adoption.

Opportunities

The global companion diagnostics market offers significant growth opportunities. These consist of the following:

Recent Developments in Next-Generation Sequencing Technology

Next-generation sequencing (NGS) is a technology used by clinicians to examine the number of genes involved in the development of cancer in a tumor that has been surgically removed from the patient. The NGS technology yields high output in a predetermined amount of time, and its technological capabilities are expanding. According to an article published by the Centres for Disease Control & Prevention (CDC), next-generation sequencing has moved from research to clinical usage over the last five years.

In addition, leading manufacturers are providing technologically improved testing solutions to the market. As a result, developments in next-generation sequencing to discover genetic anomalies, which can help cure certain diseases, are one of the most recent companion diagnostics industry trends. For example, in January 2022, Illumina, Inc. partnered with SomaLogic Operating Co. Inc. to integrate SomaScan, a proteomics test, with Illumina’s existing and future higher throughput next-generation sequencing systems.

Competitive Landscape

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Players

The companion diagnostics industry is relatively fragmented yet highly competitive, with a few big market companies. The following are a few of the most prominent market players and their market shares:

Abbott Laboratories Molecular Inc. (U.S.)
ARUP Laboratories Inc. (U.S.)
Agilent Technologies (U.S.)
Danaher Corporation (Leica Microsystems) (Germany)
BioMerieux (France)
Myriad Genetics Inc. (U.S.)
Foundation Medicine Inc. (U.S.)
Thermo Fisher Scientific (Life Technologies Corporation) (Germany)
Roche (Ventana Medical Systems Inc.) (U.S.)
QIAGEN N.V. (Germany)
Others

These major manufacturers are investing heavily in R&D to diversify their product portfolios, which will drive developments in the companion diagnostics market.

Companion diagnostics companies are also implementing a range of strategic measures, such as launching new products, entering into agreements, merging with other companies, investing more, and forming alliances with other companies to broaden their global reach.

Competitors in the companion diagnostics industry need to provide affordable solutions in order to expand and endure in a more competitive and hostile marketplace.

In October 2023, QIAGEN N.V., a molecular diagnostics firm, and Myriad Genetics, a genetic testing company, formed a strategic cooperation for the development of companion diagnostic tests for cancer. This collaboration focuses on the fabrication of lab-developed and distributable kit-based companion diagnostic assays.

In August 2023, Tempus reported that its HLA-LOH assay had received breakthrough device designation from the FDA as a companion diagnostic (CDx) test. This test will analyze sequence data with a machine-learning model.

In October 2022, HMNC Brain Health raised USD 14.2 million in a funding round to expand its precision psychiatry programs, in which drugs are co-developed with companion diagnostics to determine which patient groups may benefit from these treatments.

In February 2022, Genetron Holdings Ltd, a leading precision oncology platform company in China that specializes in early cancer screening products, molecular profiling tests, and companion diagnostics development, signed a collaboration agreement with HUTCHMED (China) Ltd to develop a highly advanced companion diagnostic.

In April 2021, Agilent Technologies Inc. acquired Resolution Bioscience Inc., a market leader in next-generation sequencing-based oncology solutions. This acquisition accelerated and increased the company’s capabilities in NGS-based cancer diagnostics, as well as providing novel technologies to satisfy the fast-growing companion diagnostics market needs.

Summary of Key Findings

The global companion diagnostics market is experiencing robust growth, owing to recent developments in personalized medicines, rising rates of cancer and other chronic medical conditions, and the need for more targeted and effective therapies.
The market is segmented by technology type, indication, end user, and region.
PCR techniques are widely employed in clinical and research laboratories for a wide range of purposes, including criminal forensics, clinical diagnosis, and biomedical research.
Reimbursement policies and coverage for companion diagnostics vary across different regions and healthcare systems, posing challenges for market penetration and adoption, particularly in markets with limited reimbursement schemes and pricing pressures.
Abbott, F. Hoffmann-La Roche Ltd, and Agilent Technologies Inc. are the market leaders as a result of their acquisitions of rival companies and the introduction of new products.

Future Outlook

PCR-based molecular assays are emerging as the dominant mechanism of pathogen detection in the event of a rapid illness outbreak, such as the current Zika and coronavirus outbreaks.
Liquid biopsy techniques are anticipated to gain widespread market adoption as non-invasive methods for companion diagnostics, offering real-time monitoring of disease progression, treatment response, and minimal residual disease detection across various cancer types.

How CXOs Can Benefit from the Credence Research Companion Diagnostics Market Report:

The Credence Research Companion Diagnostics Market Report offers CXOs a comprehensive overview of the market, covering:

Market Size and Growth Forecast: The report offers detailed estimates of the global companion diagnostics market size, segmented by technology type, indication, end user, and region. It includes forecasts for the market through 2032, highlighting key trends and drivers shaping market growth.
Market Segmentation: CXOs can gain insights into market segmentation by technology type, indication, end user, and region. This segmentation offers a detailed understanding of various market segments and the opportunities they present. For example, the emergence of mass spectrometry as a promising technology in companion diagnostics, particularly for autoimmune diseases, provides CXOs with valuable insights into niche markets and potential growth areas.
Competitive Landscape: The report profiles key players in the companion diagnostics market, providing insights into their strategies, product offerings, and financial performance. CXOs can use this information to identify and assess their competition, as well as understand the strategies employed by leading companies to differentiate themselves in the market.
Key Trends and Drivers :The report identifies and analyses the leading trends and drivers shaping the companion diagnostics market size. This information can help CXOs to make informed decisions about their investments and strategies.

CXOs can leverage insights from the Credence Research Companion Diagnostics Market Report to:

Identify Growth Opportunities: The report assists CXOs in identifying promising growth opportunities within the companion diagnostics market. For instance, the report highlights the increasing adoption of next-generation sequencing (NGS) in companion diagnostics, especially in oncology, as a key growth area.
Make Informed Investment Decisions: The report can help CXOs make informed investment decisions about companion diagnostics. For example, understanding key factors such as technological advancements and the regulatory landscape helps CXOs evaluate investment opportunities and select appropriate strategies for market entry or expansion.
Develop Competitive Strategies: CXOs can develop competitive strategies for their companion diagnostics businesses based on insights from the report. For instance, understanding competitor offerings and market dynamics allows CXOs to differentiate their products and services and gain a competitive edge in the market.
Track Market Developments: The report helps CXOs track market developments and stay ahead of the curve in the companion diagnostics market. For example, insights into the latest trends, innovations, and regulatory changes enable CXOs to adapt their strategies and capitalize on emerging opportunities.

Overall, the Credence Research Companion Diagnostics Market Report proves to be a valuable resource for CXOs seeking a deeper understanding of the market and identifying growth opportunities.

Segmentation

By Technology Type
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- In Situ Hybridization (ISH)
- Mass Spectrometry
- Others
By Indication
- Oncology
- Neurology
- Infectious Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Others
By End User
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Companion Diagnostics Market
2.1.1. Global Companion Diagnostics Market, By Technology Type
2.1.2. Global Companion Diagnostics Market, By Indication
2.1.3. Global Companion Diagnostics Market, By End User
2.1.4. Global Companion Diagnostics Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Companion Diagnostics Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Companion Diagnostics Market Drivers
3.2.2. Companion Diagnostics Market Restraints
3.2.3. Companion Diagnostics Market Opportunities
3.2.4. Major Companion Diagnostics Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Technology Type
3.5.2. Indication
3.5.3. End User
3.5.4. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Companion Diagnostics Market: Company Market Share, Value 2023
4.1.2. Global Companion Diagnostics Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Companion Diagnostics Market: Top 3 Company Market Share, Value 2023
4.2. Global Companion Diagnostics Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Companion Diagnostics Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Companion Diagnostics Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Companion Diagnostics Market, By Technology Type
8.1. Global Companion Diagnostics Market Overview, by Technology Type
8.1.1. Global Companion Diagnostics Market Revenue Share, By Technology Type, 2023 Vs 2032 (in %)
8.2. Polymerase Chain Reaction (PCR)
8.2.1. Global Companion Diagnostics Market, By Polymerase Chain Reaction (PCR), By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for Polymerase Chain Reaction (PCR)
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Immunohistochemistry (IHC)
8.3.1. Global Companion Diagnostics Market, By Immunohistochemistry (IHC), By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for Immunohistochemistry (IHC)
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Next-Generation Sequencing (NGS)
8.4.1. Global Companion Diagnostics Market, By Next-Generation Sequencing (NGS), By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for Next-Generation Sequencing (NGS)
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. In Situ Hybridization (ISH)
8.5.1. Global Companion Diagnostics Market, By In Situ Hybridization (ISH), By Region, 2019-2032 (US$ Mn)
8.5.2. Market Dynamics for In Situ Hybridization (ISH)
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Mass Spectrometry
8.6.1. Global Companion Diagnostics Market, By Mass Spectrometry, By Region, 2019-2032 (US$ Mn)
8.6.2. Market Dynamics for Mass Spectrometry
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends
8.7. Others
8.7.1. Global Companion Diagnostics Market, By Others, By Region, 2019-2032 (US$ Mn)
8.7.2. Market Dynamics for Others
8.7.2.1. Drivers
8.7.2.2. Restraints
8.7.2.3. Opportunities
8.7.2.4. Trends
9. Global Companion Diagnostics Market, By Indication
9.1. Global Companion Diagnostics Market Overview, by Indication
9.1.1. Global Companion Diagnostics Market Revenue Share, By Indication, 2023 Vs 2032 (in %)
9.2. Oncology
9.2.1. Global Companion Diagnostics Market, By Oncology, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for Oncology
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Neurology
9.3.1. Global Companion Diagnostics Market, By Neurology, By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Neurology
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Infectious Diseases
9.4.1. Global Companion Diagnostics Market, By Infectious Diseases, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Infectious Diseases
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. Cardiovascular Diseases
9.5.1. Global Companion Diagnostics Market, By Cardiovascular Diseases, By Region, 2019-2032 (US$ Mn)
9.5.2. Market Dynamics for Cardiovascular Diseases
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
9.6. Autoimmune Diseases
9.6.1. Global Companion Diagnostics Market, By Autoimmune Diseases, By Region, 2019-2032 (US$ Mn)
9.6.2. Market Dynamics for Autoimmune Diseases
9.6.2.1. Drivers
9.6.2.2. Restraints
9.6.2.3. Opportunities
9.6.2.4. Trends
9.7. Others
9.7.1. Global Companion Diagnostics Market, By Others, By Region, 2019-2032 (US$ Mn)
9.7.2. Market Dynamics for Others
9.7.2.1. Drivers
9.7.2.2. Restraints
9.7.2.3. Opportunities
9.7.2.4. Trends
10. Global Companion Diagnostics Market, By End User
10.1. Global Companion Diagnostics Market Overview, by End User
10.1.1. Global Companion Diagnostics Market Revenue Share, By End User, 2023 Vs 2032 (in %)
10.2. Hospitals
10.2.1. Global Companion Diagnostics Market, By Hospitals, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Hospitals
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Diagnostic Laboratories
10.3.1. Global Companion Diagnostics Market, By Diagnostic Laboratories, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for Diagnostic Laboratories
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Academic and Research Institutes
10.4.1. Global Companion Diagnostics Market, By Academic and Research Institutes, By Region, 2019-2032 (US$ Mn)
10.4.2. Market Dynamics for Academic and Research Institutes
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
10.5. Specialty Clinics
10.5.1. Global Companion Diagnostics Market, By Specialty Clinics, By Region, 2019-2032 (US$ Mn)
10.5.2. Market Dynamics for Specialty Clinics
10.5.2.1. Drivers
10.5.2.2. Restraints
10.5.2.3. Opportunities
10.5.2.4. Trends
10.6. Others
10.6.1. Global Companion Diagnostics Market, By Others, By Region, 2019-2032 (US$ Mn)
10.6.2. Market Dynamics for Others
10.6.2.1. Drivers
10.6.2.2. Restraints
10.6.2.3. Opportunities
10.6.2.4. Trends
11. Global Companion Diagnostics Market, By Region
11.1. Global Companion Diagnostics Market Overview, by Region
11.1.1. Global Companion Diagnostics Market, By Region, 2023 vs 2032 (in%)
11.2. Technology Type
11.2.1. Global Companion Diagnostics Market, By Technology Type, 2019-2032 (US$ Mn)
11.3. Indication
11.3.1. Global Companion Diagnostics Market, By Indication, 2019-2032 (US$ Mn)
11.4. End User
11.4.1. Global Companion Diagnostics Market, By End User, 2019-2032 (US$ Mn)
12. North America Companion Diagnostics Market Analysis
12.1. Overview
12.1.1. Market Dynamics for North America
12.1.1.1. Drivers
12.1.1.2. Restraints
12.1.1.3. Opportunities
12.1.1.4. Trends
12.2. North America Companion Diagnostics Market, by Technology Type, 2019-2032(US$ Mn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. North America Companion Diagnostics Market, by Indication, 2019-2032(US$ Mn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. North America Companion Diagnostics Market, by End User, 2019-2032(US$ Mn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. North America Companion Diagnostics Market, by Country, 2019-2032 (US$ Mn)
12.5.1. North America Companion Diagnostics Market, by Country, 2023 Vs 2032 (in%)
12.5.2. U.S.
12.5.3. Canada
12.5.4. Mexico
13. Europe Companion Diagnostics Market Analysis
13.1. Overview
13.1.1. Market Dynamics for North America
13.1.1.1. Drivers
13.1.1.2. Restraints
13.1.1.3. Opportunities
13.1.1.4. Trends
13.2. Europe Companion Diagnostics Market, by Technology Type, 2019-2032(US$ Mn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Europe Companion Diagnostics Market, by Indication, 2019-2032(US$ Mn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Europe Companion Diagnostics Market, by End User, 2019-2032(US$ Mn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. Europe Companion Diagnostics Market, by Country, 2019-2032 (US$ Mn)
13.5.1. Europe Companion Diagnostics Market, by Country, 2023 Vs 2032 (in%)
13.5.2. UK
13.5.3. France
13.5.4. Germany
13.5.5. Italy
13.5.6. Spain
13.5.7. Benelux
13.5.8. Russia
13.5.9. Rest of Europe
14. Asia Pacific Companion Diagnostics Market Analysis
14.1. Overview
14.1.1. Market Dynamics for North America
14.1.1.1. Drivers
14.1.1.2. Restraints
14.1.1.3. Opportunities
14.1.1.4. Trends
14.2. Asia Pacific Companion Diagnostics Market, by Technology Type, 2019-2032(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Asia Pacific Companion Diagnostics Market, by Indication, 2019-2032(US$ Mn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Asia Pacific Companion Diagnostics Market, by End User, 2019-2032(US$ Mn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Asia Pacific Companion Diagnostics Market, by Country, 2019-2032 (US$ Mn)
14.5.1. Asia Pacific Companion Diagnostics Market, by Country, 2023 Vs 2032 (in%)
14.5.2. China
14.5.3. Japan
14.5.4. India
14.5.5. South Korea
14.5.6. South East Asia
14.5.7. Rest of Asia Pacific
15. Latin America Companion Diagnostics Market Analysis
15.1. Overview
15.1.1. Market Dynamics for North America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. Latin America Companion Diagnostics Market, by Technology Type, 2019-2032(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Latin America Companion Diagnostics Market, by Indication, 2019-2032(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Latin America Companion Diagnostics Market, by End User, 2019-2032(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Latin America Companion Diagnostics Market, by Country, 2019-2032 (US$ Mn)
15.5.1. Latin America Companion Diagnostics Market, by Country, 2023 Vs 2032 (in%)
15.5.2. Brazil
15.5.3. Argentina
15.5.4. Rest of Latin America
16. Middle East Companion Diagnostics Market Analysis
16.1. Overview
16.1.1. Market Dynamics for North America
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Middle East Companion Diagnostics Market, by Technology Type, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Middle East Companion Diagnostics Market, by Indication, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Middle East Companion Diagnostics Market, by End User, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Middle East Companion Diagnostics Market, by Country, 2019-2032 (US$ Mn)
16.5.1. Middle East Companion Diagnostics Market, by Country, 2023 Vs 2032 (in%)
16.5.2. UAE
16.5.3. Saudi Arabia
16.5.4. Rest of Middle East
17. Africa Companion Diagnostics Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Africa Companion Diagnostics Market, by Technology Type, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Africa Companion Diagnostics Market, by Indication, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Africa Companion Diagnostics Market, by End User, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Africa Companion Diagnostics Market, by Country, 2019-2032 (US$ Mn)
17.5.1. Middle East Companion Diagnostics Market, by Country, 2023 Vs 2032 (in%)
17.5.2. South Africa
17.5.3. Egypt
17.5.4. Rest of Africa
18. Company Profiles
18.1. Abbott Laboratories Molecular Inc. (U.S.)
18.1.1. Company Overview
18.1.2. Products/Services Portfolio
18.1.3. Geographical Presence
18.1.4. SWOT Analysis
18.1.5. Financial Summary
18.1.5.1. Market Revenue and Net Profit (2019-2023)
18.1.5.2. Business Segment Revenue Analysis
18.1.5.3. Geographical Revenue Analysis
18.2. ARUP Laboratories Inc. (U.S.)
18.3. Agilent Technologies (U.S.)
18.4. Danaher Corporation (Leica Microsystems) (Germany)
18.5. BioMerieux (France)
18.6. Myriad Genetics Inc. (U.S.)
18.7. Foundation Medicine Inc. (U.S.)
18.8. Thermo Fisher Scientific (Life Technologies Corporation) (Germany)
18.9. Roche (Ventana Medical Systems Inc.) (U.S.)
18.10. QIAGEN N.V. (Germany)
18.11. Others
19. Research Methodology
19.1. Research Methodology
19.2. Phase I – Secondary Research
19.3. Phase II – Data Modelling
19.3.1. Company Share Analysis Model
19.3.2. Revenue Based Modelling
19.4. Phase III – Primary Research
19.5. Research Limitations
19.5.1. Assumptions

List of Figures
FIG. 1 Global Companion Diagnostics Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Companion Diagnostics Market Segmentation
FIG. 4 Global Companion Diagnostics Market, by Technology Type, 2023 (US$ Mn)
FIG. 5 Global Companion Diagnostics Market, by Indication, 2023 (US$ Mn)
FIG. 6 Global Companion Diagnostics Market, by End User, 2023 (US$ Mn)
FIG. 7 Global Companion Diagnostics Market, by Application, 2023 (US$ Mn)
FIG. 8 Global Companion Diagnostics Market, by Geography, 2023 (US$ Mn)
FIG. 9 Attractive Investment Proposition, by Technology Type, 2023
FIG. 10 Attractive Investment Proposition, by Indication, 2023
FIG. 11 Attractive Investment Proposition, by End User, 2023
FIG. 12 Attractive Investment Proposition, by Geography, 2023
FIG. 13 Global Market Share Analysis of Key Companion Diagnostics Market Manufacturers, 2023
FIG. 14 Global Market Positioning of Key Companion Diagnostics Market Manufacturers, 2023
FIG. 15 Global Companion Diagnostics Market Value Contribution, By Technology Type, 2023 & 2032 (Value %)
FIG. 16 Global Companion Diagnostics Market, by Polymerase Chain Reaction (PCR), Value, 2019-2032 (US$ Mn)
FIG. 17 Global Companion Diagnostics Market, by Immunohistochemistry (IHC), Value, 2019-2032 (US$ Mn)
FIG. 18 Global Companion Diagnostics Market, by Next-Generation Sequencing (NGS), Value, 2019-2032 (US$ Mn)
FIG. 19 Global Companion Diagnostics Market, by In Situ Hybridization (ISH), Value, 2019-2032 (US$ Mn)
FIG. 20 Global Companion Diagnostics Market, by Mass Spectrometry, Value, 2019-2032 (US$ Mn)
FIG. 21 Global Companion Diagnostics Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 22 Global Companion Diagnostics Market Value Contribution, By Indication, 2023 & 2032 (Value %)
FIG. 23 Global Companion Diagnostics Market, by Oncology, Value, 2019-2032 (US$ Mn)
FIG. 24 Global Companion Diagnostics Market, by Neurology, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Companion Diagnostics Market, by Infectious Diseases, Value, 2019-2032 (US$ Mn)
FIG. 26 Global Companion Diagnostics Market, by Cardiovascular Diseases, Value, 2019-2032 (US$ Mn)
FIG. 27 Global Companion Diagnostics Market, by Autoimmune Diseases, Value, 2019-2032 (US$ Mn)
FIG. 28 Global Companion Diagnostics Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 29 Global Companion Diagnostics Market Value Contribution, By End User, 2023 & 2032 (Value %)
FIG. 30 Global Companion Diagnostics Market, by Hospitals, Value, 2019-2032 (US$ Mn)
FIG. 31 Global Companion Diagnostics Market, by Diagnostic Laboratories, Value, 2019-2032 (US$ Mn)
FIG. 32 Global Companion Diagnostics Market, by Academic and Research Institutes, Value, 2019-2032 (US$ Mn)
FIG. 33 Global Companion Diagnostics Market, by Specialty Clinics, Value, 2019-2032 (US$ Mn)
FIG. 34 Global Companion Diagnostics Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 35 North America Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 36 U.S. Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 37 Canada Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 38 Mexico Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 39 Europe Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 40 Germany Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 41 France Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 42 U.K. Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 43 Italy Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 44 Spain Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 45 Benelux Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 46 Russia Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 47 Rest of Europe Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 48 Asia Pacific Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 49 China Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 50 Japan Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 51 India Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 52 South Korea Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 53 South-East Asia Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 54 Rest of Asia Pacific Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 55 Latin America Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 56 Brazil Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 57 Argentina Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 58 Rest of Latin America Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 59 Middle East Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 60 UAE Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 61 Saudi Arabia Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 62 Rest of Middle East Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 63 Africa Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 64 South Africa Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 65 Egypt Companion Diagnostics Market, 2019-2032 (US$ Mn)
FIG. 66 Rest of Africa Companion Diagnostics Market, 2019-2032 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Companion Diagnostics Market
TABLE 2 Global Companion Diagnostics Market: Market Drivers Impact Analysis
TABLE 3 Global Companion Diagnostics Market: Market Restraints Impact Analysis
TABLE 4 Global Companion Diagnostics Market, by Competitive Benchmarking, 2023
TABLE 5 Global Companion Diagnostics Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Companion Diagnostics Market, by Key Strategies Analysis, 2023
TABLE 7 Global Companion Diagnostics Market, by Polymerase Chain Reaction (PCR), By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Companion Diagnostics Market, by Polymerase Chain Reaction (PCR), By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Companion Diagnostics Market, by Immunohistochemistry (IHC), By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Companion Diagnostics Market, by Immunohistochemistry (IHC), By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Companion Diagnostics Market, by Next-Generation Sequencing (NGS), By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Companion Diagnostics Market, by Next-Generation Sequencing (NGS), By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Companion Diagnostics Market, by In Situ Hybridization (ISH), By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Companion Diagnostics Market, by In Situ Hybridization (ISH), By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Companion Diagnostics Market, by Mass Spectrometry, By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Companion Diagnostics Market, by Mass Spectrometry, By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Companion Diagnostics Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Companion Diagnostics Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Companion Diagnostics Market, by Oncology, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Companion Diagnostics Market, by Oncology, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Companion Diagnostics Market, by Neurology, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Companion Diagnostics Market, by Neurology, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Companion Diagnostics Market, by Infectious Diseases, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Companion Diagnostics Market, by Infectious Diseases, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Companion Diagnostics Market, by Cardiovascular Diseases, By Region, 2019-2023 (US$ Mn)
TABLE 26 Global Companion Diagnostics Market, by Cardiovascular Diseases, By Region, 2024-2032 (US$ Mn)
TABLE 27 Global Companion Diagnostics Market, by Autoimmune Diseases, By Region, 2019-2023 (US$ Mn)
TABLE 28 Global Companion Diagnostics Market, by Autoimmune Diseases, By Region, 2024-2032 (US$ Mn)
TABLE 29 Global Companion Diagnostics Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 30 Global Companion Diagnostics Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 31 Global Companion Diagnostics Market, by Hospitals, By Region, 2019-2023 (US$ Mn)
TABLE 32 Global Companion Diagnostics Market, by Hospitals, By Region, 2024-2032 (US$ Mn)
TABLE 33 Global Companion Diagnostics Market, by Diagnostic Laboratories, By Region, 2019-2023 (US$ Mn)
TABLE 34 Global Companion Diagnostics Market, by Diagnostic Laboratories, By Region, 2024-2032 (US$ Mn)
TABLE 35 Global Companion Diagnostics Market, by Academic and Research Institutes, By Region, 2019-2023 (US$ Mn)
TABLE 36 Global Companion Diagnostics Market, by Academic and Research Institutes, By Region, 2024-2032 (US$ Mn)
TABLE 37 Global Companion Diagnostics Market, by Specialty Clinics, By Region, 2019-2023 (US$ Mn)
TABLE 38 Global Companion Diagnostics Market, by Specialty Clinics, By Region, 2024-2032 (US$ Mn)
TABLE 39 Global Companion Diagnostics Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 40 Global Companion Diagnostics Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 41 Global Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 42 Global Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 43 Global Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 44 Global Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 45 Global Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 46 Global Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 47 Global Companion Diagnostics Market, by Region, 2019-2023 (US$ Mn)
TABLE 48 Global Companion Diagnostics Market, by Region, 2024-2032 (US$ Mn)
TABLE 49 North America Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 50 North America Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 51 North America Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 52 North America Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 53 North America Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 54 North America Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 55 North America Companion Diagnostics Market, by Country, 2019-2023 (US$ Mn)
TABLE 56 North America Companion Diagnostics Market, by Country, 2024-2032 (US$ Mn)
TABLE 57 United States Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 58 United States Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 59 United States Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 60 United States Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 61 United States Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 62 United States Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 63 Canada Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 64 Canada Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 65 Canada Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 66 Canada Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 67 Canada Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 68 Canada Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 69 Mexico Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 70 Mexico Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 71 Mexico Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 72 Mexico Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 73 Mexico Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 74 Mexico Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 75 Europe Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 76 Europe Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 77 Europe Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 78 Europe Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 79 Europe Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 80 Europe Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 81 Europe Companion Diagnostics Market, by Country, 2019-2023 (US$ Mn)
TABLE 82 Europe Companion Diagnostics Market, by Country, 2024-2032 (US$ Mn)
TABLE 83 Germany Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 84 Germany Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 85 Germany Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 86 Germany Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 87 Germany Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 88 Germany Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 89 France Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 90 France Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 91 France Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 92 France Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 93 France Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 94 France Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 95 United Kingdom Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 96 United Kingdom Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 97 United Kingdom Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 98 United Kingdom Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 99 United Kingdom Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 100 United Kingdom Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 101 Italy Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 102 Italy Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 103 Italy Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 104 Italy Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 105 Italy Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 106 Italy Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 107 Spain Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 108 Spain Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 109 Spain Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 110 Spain Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 111 Spain Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 112 Spain Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 113 Benelux Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 114 Benelux Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 115 Benelux Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 116 Benelux Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 117 Benelux Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 118 Benelux Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 119 Russia Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 120 Russia Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 121 Russia Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 122 Russia Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 123 Russia Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 124 Russia Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 125 Rest of Europe Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 126 Rest of Europe Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 127 Rest of Europe Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 128 Rest of Europe Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 129 Rest of Europe Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 130 Rest of Europe Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 131 Asia Pacific Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 132 Asia Pacific Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 133 Asia Pacific Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 134 Asia Pacific Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 135 Asia Pacific Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 136 Asia Pacific Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 137 China Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 138 China Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 139 China Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 140 China Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 141 China Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 142 China Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 143 Japan Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 144 Japan Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 145 Japan Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 146 Japan Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 147 Japan Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 148 Japan Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 149 India Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 150 India Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 151 India Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 152 India Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 153 India Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 154 India Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 155 South Korea Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 156 South Korea Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 157 South Korea Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 158 South Korea Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 159 South Korea Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 160 South Korea Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 161 South-East Asia Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 162 South-East Asia Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 163 South-East Asia Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 164 South-East Asia Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 165 South-East Asia Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 166 South-East Asia Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 167 Rest of Asia Pacific Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 168 Rest of Asia Pacific Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 169 Rest of Asia Pacific Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 170 Rest of Asia Pacific Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 171 Rest of Asia Pacific Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 172 Rest of Asia Pacific Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 173 Latin America Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 174 Latin America Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 175 Latin America Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 176 Latin America Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 177 Latin America Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 178 Latin America Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 179 Brazil Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 180 Brazil Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 181 Brazil Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 182 Brazil Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 183 Brazil Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 184 Brazil Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 185 Argentina Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 186 Argentina Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 187 Argentina Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 188 Argentina Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 189 Argentina Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 190 Argentina Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 191 Rest of Latin America Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 192 Rest of Latin America Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 193 Rest of Latin America Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 194 Rest of Latin America Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 195 Rest of Latin America Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 196 Rest of Latin America Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 197 Middle East Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 198 Middle East Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 199 Middle East Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 200 Middle East Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 201 Middle East Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 202 Middle East Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 203 UAE Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 204 UAE Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 205 UAE Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 206 UAE Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 207 UAE Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 208 UAE Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 209 Saudi Arabia Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 210 Saudi Arabia Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 211 Saudi Arabia Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 212 Saudi Arabia Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 213 Saudi Arabia Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 214 Saudi Arabia Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 215 Rest of Middle East Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 216 Rest of Middle East Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 217 Rest of Middle East Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 218 Rest of Middle East Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 219 Rest of Middle East Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 220 Rest of Middle East Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 221 Africa Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 222 Africa Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 223 Africa Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 224 Africa Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 225 Africa Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 226 Africa Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 227 South Africa Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 228 South Africa Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 229 South Africa Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 230 South Africa Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 231 South Africa Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 232 South Africa Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 233 Egypt Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 234 Egypt Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 235 Egypt Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 236 Egypt Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 237 Egypt Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 238 Egypt Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)
TABLE 239 Rest of Africa Companion Diagnostics Market, by Technology Type, 2019-2023 (US$ Mn)
TABLE 240 Rest of Africa Companion Diagnostics Market, by Technology Type, 2024-2032 (US$ Mn)
TABLE 241 Rest of Africa Companion Diagnostics Market, by Indication, 2019-2023 (US$ Mn)
TABLE 242 Rest of Africa Companion Diagnostics Market, by Indication, 2024-2032 (US$ Mn)
TABLE 243 Rest of Africa Companion Diagnostics Market, by End User, 2019-2023 (US$ Mn)
TABLE 244 Rest of Africa Companion Diagnostics Market, by End User, 2024-2032 (US$ Mn)

Frequently Asked Questions:

What is the current size of the global companion diagnostics market?

The global companion diagnostics market was valued at USD 5815.2 Million in 2023.

What is the expected growth rate of the companion diagnostics market between 2024 and 2032?

The companion diagnostics market is estimated to grow at a CAGR of 13.3% between 2024 and 2032, reaching USD 17890.97 Million in 2032.

Which category is leading the revenue share in terms of technology type?

Next-generation sequencing (NGS) is the leading segment by technology type, holding over 25% market share in value in 2023.

Which region is fueling the growth of the companion diagnostics industry?

North America is primarily credited for developments in the intraosseous device industry, contributing to more than one-third of the overall market share in 2023.

Who are the major players in the global companion diagnostics market?

The top players include Abbott Laboratories Molecular Inc. (U.S.), ARUP Laboratories Inc. (U.S.), Agilent Technologies (U.S.), Danaher Corporation (Leica Microsystems) (Germany), BioMerieux (France), Myriad Genetics Inc. (U.S.), Foundation Medicine Inc. (U.S.), Thermo Fisher Scientific (Life Technologies Corporation) (Germany), Roche (Ventana Medical Systems Inc.) (U.S.), QIAGEN N.V. (Germany), and Others.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –